SAMHD1 and neoplasm: The clinically approved drug pimitespib44–46 and IPI-504 also induced the depletion of SAMHD1 in HEK293T cells and in various tumor cell types (AGS, H9, HGC-27, and HeLa) (Fig. 3c, d; Supplementary Fig. 3c, h).